
Sign up to save your podcasts
Or


In this company introduction, we speak with David Elsley, President & CEO of Cardiol Therapeutics (NASDAQ/TSX: CRDL), a clinical-stage life sciences company focused on developing therapies to address inflammation-driven cardiovascular diseases.
Cardiol’s lead asset, CardiolRx™, is currently in:
We also cover:
Please email me any further questions you have for David. My email address is [email protected].
Click here to learn more about Cardiol Therapeutics.
By KE Report4.3
1111 ratings
In this company introduction, we speak with David Elsley, President & CEO of Cardiol Therapeutics (NASDAQ/TSX: CRDL), a clinical-stage life sciences company focused on developing therapies to address inflammation-driven cardiovascular diseases.
Cardiol’s lead asset, CardiolRx™, is currently in:
We also cover:
Please email me any further questions you have for David. My email address is [email protected].
Click here to learn more about Cardiol Therapeutics.

5,685 Listeners

3,074 Listeners

378 Listeners

148 Listeners

932 Listeners

94 Listeners

252 Listeners

91 Listeners

1,351 Listeners

122 Listeners

377 Listeners

404 Listeners

59 Listeners

46 Listeners

145 Listeners